These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38344732)

  • 1. An Initial Low-Dose Etelcalcetide Dosing Strategy in Hemodialysis Patients With Moderate Secondary Hyperparathyroidism is Effective and Cost-Saving.
    Carta A; Tedesco M; Mescia F; Manenti C; Lucca B; Verzeletti F; Guerini A; Terni FG; Zubani R; Guerini S; Valzorio B; Jeannin G; Carli O; Camerini C; Possenti S; Gaggia P; Alberici F
    Kidney Int Rep; 2024 Feb; 9(2):482-485. PubMed ID: 38344732
    [No Abstract]   [Full Text] [Related]  

  • 2. Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients.
    Karaboyas A; Muenz D; Fuller DS; Desai P; Lin TC; Robinson BM; Rossetti S; Pisoni RL
    Am J Kidney Dis; 2022 Mar; 79(3):362-373. PubMed ID: 34273436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Experience of Using Etelcalcetide for Secondary Hyperparathyroidism in Community-Based Hemodialysis Centers in Singapore.
    Khan BA; Qu X; Hua Y; Javaid MM
    Cureus; 2023 Nov; 15(11):e48186. PubMed ID: 38050530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term use of etelcalcetide for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis for end-stage renal failure: a real-life retrospective observational study.
    Morosetti M; Jankovic L; Zappalà L; Agafonova E; Pryshlyak I
    Int Urol Nephrol; 2023 Jul; 55(7):1865-1873. PubMed ID: 36790677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current therapeutic options for the treatment of secondary hyperparathyroidism in end-stage renal disease patients treated with hemodialysis: a 12-month comparative study.
    Dudar I; Shifris I; Dudar S; Kulish V
    Pol Merkur Lekarski; 2022 Oct; 50(299):294-298. PubMed ID: 36283011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism.
    Shigematsu T; Fukagawa M; Yokoyama K; Akiba T; Fujii A; Odani M; Akizawa T;
    Clin Exp Nephrol; 2018 Apr; 22(2):426-436. PubMed ID: 28836058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis.
    Wolf M; Block GA; Chertow GM; Cooper K; Fouqueray B; Moe SM; Sun Y; Tomlin H; Vervloet M; Oberbauer R
    Clin Kidney J; 2020 Feb; 13(1):75-84. PubMed ID: 32082556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real World Use and Effects of Calcimimetics in Treating Mineral and Bone Disorder in Hemodialysis Patients.
    Danese MD; Lubeck D; Belozeroff V; Lin TC; Desai P; Gleeson M; Martin K; Chonchol M
    Am J Nephrol; 2020; 51(10):815-822. PubMed ID: 32966995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case of a hemodialysis patient with secondary hyperparathyroidism who was resistant to etelcalcetide treatment but not to cinacalcet hydrochloride.
    Nakamura H; Tokumoto M; Anayama M; Kurihara S; Makino Y; Tamura K; Nagasawa M
    CEN Case Rep; 2022 May; 11(2):254-258. PubMed ID: 34787825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials.
    Block GA; Bushinsky DA; Cunningham J; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Mix TC; Moe SM; Patel UD; Silver J; Spiegel DM; Sterling L; Walsh L; Chertow GM
    JAMA; 2017 Jan; 317(2):146-155. PubMed ID: 28097355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy.
    Friedl C; Zitt E
    Drug Des Devel Ther; 2018; 12():1589-1598. PubMed ID: 29910605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcimimetic use in US hemodialysis facilities in first 2 years after the launch of etelcalcetide: A descriptive analysis of real-world clinical practice and outcomes.
    Stephens JM; Fox KM; Desai P; Cheng S; Goodman WG; Kendrick JB
    Hemodial Int; 2022 Apr; 26(2):243-254. PubMed ID: 34931443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
    Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
    JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-term efficacy and safety of etelcalcetide in hemodialysis patients with severe secondary hyperparathyroidism].
    Massimetti C; Tondo M; Feriozzi S
    G Ital Nefrol; 2020 Oct; 37(5):. PubMed ID: 33026204
    [No Abstract]   [Full Text] [Related]  

  • 15. Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis.
    Chen P; Narayanan A; Wu B; Gisleskog PO; Gibbs JP; Chow AT; Melhem M
    Clin Pharmacokinet; 2018 Jan; 57(1):71-85. PubMed ID: 28508378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the potential value of improved care for secondary hyperparathyroidism with a novel calcimimetic therapy.
    Stollenwerk B; Iannazzo S; Cooper K; Belozeroff V
    J Med Econ; 2017 Oct; 20(10):1110-1115. PubMed ID: 28803497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of secondary hyperparathyroidism: How do cinacalcet and etelcalcetide differ?
    Eidman KE; Wetmore JB
    Semin Dial; 2018 Sep; 31(5):440-444. PubMed ID: 30009474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Pharmacokinetics and Pharmacodynamics of Etelcalcetide, a Novel Calcimimetic for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis.
    Wu B; Melhem M; Subramanian R; Chen P; Jaramilla Sloey B; Fouqueray B; Hock MB; Skiles GL; Chow AT; Lee E
    J Clin Pharmacol; 2018 Jun; 58(6):717-726. PubMed ID: 29534286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Effects of Etelcalcetide and Maxacalcitol on Serum Calcification Propensity in Secondary Hyperparathyroidism: A Randomized Clinical Trial.
    Shoji T; Nakatani S; Kabata D; Mori K; Shintani A; Yoshida H; Takahashi K; Ota K; Fujii H; Ueda S; Nishi S; Nakatani T; Yoshiyama M; Goto K; Hamada T; Imanishi M; Ishimura E; Kagitani S; Kato Y; Kumeda Y; Maekawa K; Matsumura T; Nagayama H; Obi Y; Ohno Y; Sai Y; Sakurai M; Sasaki S; Shidara K; Shoji S; Tsujimoto Y; Yamakawa K; Yasuda H; Yodoi S; Inaba M; Emoto M
    Clin J Am Soc Nephrol; 2021 Apr; 16(4):599-612. PubMed ID: 33685864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism.
    Block GA; Chertow GM; Sullivan JT; Deng H; Mather O; Tomlin H; Serenko M
    PLoS One; 2019; 14(3):e0213774. PubMed ID: 30875390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.